Unit
Rheumatologie
RHEUMA · Dept. I
Diagnostische Herausforderungen bei einem 54-jährigen Mann mit einer Kleingefässvaskulitis
Padberg Sgier B, Veraguth K, Median D, Niklaus M, Rubbert-Roth A, Glaser-Gallion F, Neumann T. Diagnostische Herausforderungen bei einem 54-jährigen Mann mit einer Kleingefässvaskulitis. Swiss Med Forum 2020; 20:466-468.
Jul 29, 2020Diagnostische Herausforderungen bei einem 54-jährigen Mann mit einer Kleingefässvaskulitis
Jul 29, 2020Swiss Med Forum 2020; 20:466-468
Padberg Sgier Barbara-Christina, Veraguth Katja, Median Daniela, Niklaus Monique, Rubbert-Roth Andrea, Glaser-Gallion Florian, Neumann Thomas
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Kedor C, Specker C, Seipelt E, Schulze-Koops H, Rubbert-Roth A, Kekow J, Henes J, Blank N, Behrens F, Weiß A, Zernicke J, Listing J, Feist E. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 2020; 79:1090-1097.
May 13, 2020Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
May 13, 2020Ann Rheum Dis 2020; 79:1090-1097
Kedor Claudia, Specker Christof, Seipelt Eva, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Kekow Joern, Henes Joerg Christoph, Blank Norbert, Behrens Frank, Weiß Anja, Zernicke Jan, Listing Joachim, Feist Eugen
Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
Pirker I, Rubbert-Roth A, von Kempis J, Fehr M, Neumann T. Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy. Clin Exp Rheumatol 2020
Jan 28, 2020Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
Jan 28, 2020Clin Exp Rheumatol 2020
Pirker Ian, Rubbert-Roth Andrea, von Kempis Johannes, Fehr Martin, Neumann Thomas
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
van der Heijde D, Mariette X, Li Z, Koloumas M, Huizinga T, Hetland M, Gottenberg J, Gossec L, Finckh A, Emery P, Müller-Ladner U, Mysler E, da Silva J, Westhovens R, Voshaar M, Takeuchi T, Strangfeld A, Saag K, Ruyssen-Witrand A, Rubbert-Roth A, Pope J, Poór G, van Eijk-Hustings Y, Edwards C, Cutolo M, de Wit M, van Vollenhoven R, Sepriano A, McInnes I, Kerschbaumer A, Dougados M, Burmester G, Bijlsma J, Landewé R, Aletaha D, Aringer M, Askling J, Codreanu C, De Cock D, Cardiel M, Caporali R, Buttgereit F, Buch M, den Broeder A, Boers M, Balsa A, Smolen J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685-699.
Jan 22, 2020EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Jan 22, 2020Ann Rheum Dis 2020; 79:685-699
van der Heijde Désirée, Mariette Xavier, Li Zhanguo, Koloumas Marios, Huizinga Tom W J, Hetland Merete Lund, Gottenberg Jacques-Eric, Gossec Laure, Finckh Axel, Emery Paul, Müller-Ladner Ulf, Mysler Eduardo F, da Silva Jose A P, Westhovens René, Voshaar Marieke, Takeuchi Tsutomu, Strangfeld Anja, Saag Kenneth G, Ruyssen-Witrand Adeline, Rubbert-Roth Andrea, Pope Janet E, Poór Gyula, van Eijk-Hustings Yvonne, Edwards Christopher John, Cutolo Maurizio, de Wit Maarten, van Vollenhoven Ronald F, Sepriano Alexandre, McInnes Iain B, Kerschbaumer Andreas, Dougados Maxime, Burmester Gerd R, Bijlsma Johannes W J, Landewé Robert B M, Aletaha Daniel, Aringer Martin, Askling John, Codreanu Catalin, De Cock Diederik, Cardiel Mario Humberto, Caporali Roberto, Buttgereit Frank, Buch Maya H, den Broeder Alfons A, Boers Maarten, Balsa Alejandro, Smolen Josef S
Aktue Nackenschmerzen mit seltener Ursache
Pirker I. Aktue Nackenschmerzen mit seltener Ursache. Swiss Med Forum 2020; 20(0304):50-52.
Jan 15, 2020Aktue Nackenschmerzen mit seltener Ursache
Jan 15, 2020Swiss Med Forum 2020; 20(0304):50-52
Pirker Ian
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier R. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med 2020; 383:1511-1521.
Jan 15, 2020Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Jan 15, 2020N Engl J Med 2020; 383:1511-1521
Rubbert-Roth Andrea, Enejosa Jeffrey, Pangan Aileen L, Haraoui Boulos, Rischmueller Maureen, Khan Nasser, Zhang Ying, Martin Naomi, Xavier Ricardo M
Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply
Mahr A, Specks U, Jayne D. Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. Rheumatology (Oxford) 2020; 59:1187.
Jan 1, 2020Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply
Jan 1, 2020Rheumatology (Oxford) 2020; 59:1187
Mahr Alfred, Specks Ulrich, Jayne David
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
Lyons P, Moosig F, Neumann T, Ohlsson S, Quickert S, Ramirez G, Rewerska B, Schett G, Sinico R, Szczeklik W, Tesar V, Vukcevic D, European Vasculitis Genetics Consortium, Terrier B, Watts R, Vaglio A, Holle J, Wallace C, Martorana D, Little M, Peters J, Alberici F, Liley J, Coulson R, Astle W, Baldini C, Francesco B, Cid M, Elding H, Emmi G, Epplen J, Guillevin L, Jayne D, Jiang T, Gunnarsson I, Lamprecht P, Leslie S, Smith K. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 2019; 10:5120.
Nov 12, 2019Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
Nov 12, 2019Nat Commun 2019; 10:5120
Lyons Paul A, Moosig Frank, Neumann Thomas, Ohlsson Sophie, Quickert Stefanie, Ramirez Giuseppe A, Rewerska Barbara, Schett Georg, Sinico Renato A, Szczeklik Wojciech, Tesar Vladimir, Vukcevic Damjan, European Vasculitis Genetics Consortium, Terrier Benjamin, Watts Richard A, Vaglio Augusto, Holle Julia U, Wallace Chris, Martorana Davide, Little Mark A, Peters James E, Alberici Federico, Liley James, Coulson Richard M R, Astle William, Baldini Chiara, Francesco Bonatti, Cid María C, Elding Heather, Emmi Giacomo, Epplen Jörg, Guillevin Loic, Jayne David R W, Jiang Tao, Gunnarsson Iva, Lamprecht Peter, Leslie Stephen, Smith Kenneth G C
Should we combine biologics with methotrexate in axial spondyloarthritis?
Poddubnyy D, Amital H, Rubbert-Roth A. Should we combine biologics with methotrexate in axial spondyloarthritis?. Autoimmun Rev 2019; 18:102402.
Oct 24, 2019Should we combine biologics with methotrexate in axial spondyloarthritis?
Oct 24, 2019Autoimmun Rev 2019; 18:102402
Poddubnyy Denis, Amital Howard, Rubbert-Roth Andrea
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents
Rubbert-Roth A, Szabó M, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 2019; 18:102398.
Oct 19, 2019Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents
Oct 19, 2019Autoimmun Rev 2019; 18:102398
Rubbert-Roth Andrea, Szabó Melinda Zsuzsanna, Kedves Melinda, Nagy György, Atzeni Fabiola, Sarzi-Puttini Piercarlo
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Burmester G, Boklage S, St John G, Thangavelu K, Gervitz L, Pena-Rossi C, Gómez-Centeno A, Raskina T, Amital H, Rubbert-Roth A, Strand V, Genovese M. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open 2019; 5:e001017.
Oct 18, 2019Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Oct 18, 2019RMD Open 2019; 5:e001017
Burmester Gerd R, Boklage Susan, St John Gregory, Thangavelu Karthinathan, Gervitz Leon, Pena-Rossi Claudia, Gómez-Centeno Antonio, Raskina Tatiana, Amital Howard, Rubbert-Roth Andrea, Strand Vibeke, Genovese Mark C
Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Upregulated with Therapeutic Fasting in Humans and Diet Fat Withdrawal in Obese Mice
Galli E, Rossi J, Neumann T, Andressoo J, Drinda S, Lindholm P. Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Upregulated with Therapeutic Fasting in Humans and Diet Fat Withdrawal in Obese Mice. Sci Rep 2019; 9:14318.
Oct 4, 2019Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Upregulated with Therapeutic Fasting in Humans and Diet Fat Withdrawal in Obese Mice
Oct 4, 2019Sci Rep 2019; 9:14318
Galli Emilia, Rossi Jari, Neumann Thomas, Andressoo Jaan-Olle, Drinda Stefan, Lindholm Päivi
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. J Clin Med 2019; 8
Sep 26, 2019Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Sep 26, 2019J Clin Med 2019; 8
Mueller Ruediger B, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Hasler Paul, Souza Alexander, Durmisi Mirsada, Mattow Frederik, Popp Florian, Hasler Caroline, von Kempis Johannes
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin Exp Rheumatol 2019; 37:937-945.
Apr 16, 2019Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Apr 16, 2019Clin Exp Rheumatol 2019; 37:937-945
Dörner Thomas, Peters Marvin A, Schwenke Holger, Rubbert-Roth Andrea, Krüger Klaus, Kurthen Reiner, Kellner Herbert, Kästner Peter, Engel Andreas, Schmalzing Marc, Iking-Konert Christof, Burmester Gerd-Rüdiger, Schulze-Koops Hendrik, Tony Hans-Peter
[Pulmonary involvement in rheumatoid arthritis]
Krause A, Rubbert-Roth A. [Pulmonary involvement in rheumatoid arthritis]. Z Rheumatol 2019; 78:228-235.
Apr 1, 2019[Pulmonary involvement in rheumatoid arthritis]
Apr 1, 2019Z Rheumatol 2019; 78:228-235
Krause A, Rubbert-Roth Andrea
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger P, Vallelian F, Schaer D, Mueller R. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly 2019; 149:w20022.
Mar 10, 2019Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
Mar 10, 2019Swiss Med Wkly 2019; 149:w20022
von Kempis Johannes, Duetsch Sabine, Reuschling Nicola, Villiger Rahel, Villiger Peter M, Vallelian Florence, Schaer Dominik J, Mueller Ruediger B
51-year-old man with with acute coronary syndrome and bipulmonary infiltrates
von Kempis J, Deutsche S, Reschling N, Villiger R, Villiger P, Vallelian F, Scher D, Mueller R. 51-year-old man with with acute coronary syndrome and bipulmonary infiltrates. Swiss Medical Weekly 2019; 2019;149:w20022
Mar 10, 201951-year-old man with with acute coronary syndrome and bipulmonary infiltrates
Mar 10, 2019Swiss Medical Weekly 2019; 2019;149:w20022
von Kempis Johannes, Deutsche Sabine, Reschling Nicola, Villiger Rahel, Villiger Peter M, Vallelian Florence, Scher Dominik, Mueller Ruediger B
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mueller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J Clin Med 2019; 8
Mar 3, 2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mar 3, 2019J Clin Med 2019; 8
Mueller Ruediger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Müller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine 2019; 8:302.
Mar 3, 2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mar 3, 2019Journal of Clinical Medicine 2019; 8:302
Müller Rüdiger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
Important differential diagnosis in acute tenosynovitis
Pirker I, Rein P, von Kempis J. Important differential diagnosis in acute tenosynovitis. BMJ Case Rep 2019; 12
Jan 10, 2019Important differential diagnosis in acute tenosynovitis
Jan 10, 2019BMJ Case Rep 2019; 12
Pirker Ian Franz Josef, Rein Philipp, von Kempis Johannes